Author: abhishek

Stents

Yukon Choice PC

Post author By abhishek
Post date August 14, 2022

Yukon Choice PC

Sirolinus Eluting Coronary Stent System

New generation DES providing synergy of Biodegradable Polymer with microporous surface to enhance optimal performance

Less Polymeric Load Compared To Other DES

One million pores per cm² with an average depth of 2 µm ensures optimum drug release with minimal use of polymer

Top coat with Shellac Resin ensures better polymer- drug binding with negligible polymer flaking during stent expansion

Drug and polymer are co-released in 6-9 months leaving behind bare metal stent surface

Better Endothelialisation & Superior Strut Coverage

Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue

No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

TECHNICAL DATA

PRODUCT MATRIX / ORDERING INFORMATION*

COMPLIANCE CHART

Stents

Yukon Choice PC Elite

Post author By abhishek
Post date August 14, 2022

Yukon Choice PC Elite

Sirolimus Eluting Coronary Stent System

The 1st DES to provide the synergy of Biodegradable Polymer with microporous surface protected with thermal insulation packing and electronic monitoring device for high quality and optimal performance

Setting New Standards of Quality Control

At temperatures beyond 8-25°C, Sirolimus develops oxidative degradation or Group-II impurities which may impact the potency of the drug.

To ensure protection from various environmental conditions, Yukon Choice PC Elite is equipped with Polystrene Thermal Insulation Packing.

The thermal insulated pack is further monitored by an electronic monitoring device Tag Alert manufactured by SENSITECH USA

Less Polymeric Load Compared to Other DES

Sirolimus:

It is a well-studied and clinically proven Immunosu

One million pores per cm² with average depth of 2 µm ensures optimum drug release with 1/4th of polymeric load as compared to other DES.

Top coat with Shellac Resin ensures better polymer drug binding with negligible polymer flaking during stent expansion.

ppressant. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mammalian target of rapamycin inhibition (mTOR).

Stents

VIVO ISAR

Post author By abhishek
Post date August 14, 2022

VIVO ISAR

Polymer-Free Sirolimus Eluting Stent

Future Beyond Polymers

Polymers (Durable or Biocompatible) are an integral part of Drug Release Matrix in current generation DES as they ensure the Release Kinetics of the active drug, the critical determinant of antirestenotic efficacy. However, the mechanical properties of the Metallic Cage and Aggressive Inflammatory Reactions during polymer erosion are known to cause.

Persistent Fibrin Deposition

Delayed Endothelialisation

Chronic Inflammation

Persistent Platelet Activation

Current DES Polymers are often associated with Flaking, Webbing and Peeling which leads to impaired action of active drug.

VIVO ISAR is an innovative technology which eliminates the use of Polymer by using Dual Drug Technology: Sirolimus and Probucol

Sirolimus:

It is a well-studied and clinically proven Immunosuppressant. It inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2) through mammalian target of rapamycin inhibition (mTOR).

Probucol:

It is historically proven to impose anti-restenosis effects through anti-oxidative and direct anti-proliferative effects. Though in VIVO ISAR, it is not used as an Active Pharmaceutical Ingredient.

Probucol here mimics the role of a Polymer thus functioning as a drug carrier. Probucol is used as a Matrix-Builder for the controlled release of Sirolimus. Probucol binds the drug on the stent and its properties of being hydrophobic and anti-oxidative, facilitates a controlled and continuous drug release.

Stents

ISAR SUMMIT

Post author By abhishek
Post date August 14, 2022

ISAR SUMMIT

Polymer Free Everolimus Eluting Stent

TECHNOLOGY THAT SHALL REDEFINE THE PERFORMANCE OF DRUG ELUTING STENTS

Probucol for Optimal Drug Release

Probucol obviates the Polymer related side effects of Acute Thrombogenicity, Inflammation, Delayed arterial healing.

Due to its high lipophilicity it facilitates retardation of Everolimus release in similar manner to that achieved by polymers.

Probucol and Everolimus co-release upto 80% in 28 days.*

Probucol is a well studied drug at a much higher does (upto 500 mg) oral dosage with proven safety.

ORDERING INFORMATION

COMPLIANCE CHART

Peripheral

iCover

Post author By abhishek
Post date August 13, 2022

Oceanus

BX covered stent
You deserve visibility

PRODUCT FEATURES

Unique visibility

Unique balloon-expandable (BX) stent with radiopaque markers to facilitate the implantation and the post-expansion.

Excellent navigability and conformability

Outstanding flexibility
Small profiles
Best in class post-expansion capacity (≥2mm)

iVascular proprietary encapsulation technology

Proprietary technology to encapsulate the stent into an inner and outer ePTFE layer.

Ensures a complete encapsulation avoiding delamination.

Peripheral

Oceanus

Post author By abhishek
Post date August 13, 2022

Oceanus

PTA peripheral balloon

PRODUCT FEATURES

Oceanus 14 pro

Designed for the most complex and distal lesions

Oceanus 18

Designed for all types of lesions in distal and proximal arteries

Oceanus 35

Designed for the proximal
lesions

Best flexibility and trackability

The smallest balloons (<2.5mm) have flexible tungsten markers and the bigger ones (>2.5mm) have Pt/Ir markers to ensure a good visibility.

High pushability and trackability

Excellent pushability in the proximal part and flexibility at the distal part.

High pushability

Ultra small balloons

Diameter: 1.25mm.
Length: 10 and 15 mm.

Smallest profiles

To cross the most complex lesions.

Long catheter lengthsy

170 and 200cm catheter available.

Peripheral

Angiolite BTK

Post author By abhishek
Post date August 13, 2022

Angiolite BTK

Sirolimus eluting peripheral stent

PRODUCT FEATURES

Stent Design

High radial force with mínimum recoil to be able to treat BTK lesions.

Specifically designed for homogeneous arterial coverage.

Coating technology

TransferWise, the iVascular proprietary technology that provides a homogenous drug elution that translates into lower rates of restenosis and inflammation score.
Our fluoro-acrylate polymer provides an early endothelialization and creates a thromboresistant layer.

CLINICAL SUPPORT

Angiolite BTK has demonstrated its safety and efficacy in the following clinical trial:

ANGIOLITE BTK Trial

Prospective, real-life trial in BTK lesions. 88% PP at 6 months.

Peripheral

Sergeant

Post author By abhishek
Post date August 13, 2022

Sergeant

Peripheral support catheter
To lead complex lesion procedures

PRODUCT FEATURES

Support to cross all lesions

Braided catheter with exceptional pushability and torque capacity.
Wide portfolio: 0.014”, 0.018” and 0.035” guidewire compatibility.

Able to go through tortuous arteries

Small profiles, all portfolio has 4Fr introducer compatibility.

Perfect visibility

The 4 radiopaque markers assess accurately:

Catheter position.
Lesion length.

Peripheral

Restorer

Post author By abhishek
Post date August 13, 2022

Restorer

Peripheral stent system
The illiac solution

PRODUCT FEATURES

Outstading catheter

Crimped on an Oceanus 35, offering short deflation times and great pushability and trackability.

Great profiles

6F compatible for all diameters.

Unique stent design

Provides superior conformability to the vessel wall.

Low restenosis

Advance manufacturing process to minimise the potential restenosis.

Q six, the certified quality of all iVascular stents

No random picking ensuring an automatized analysis of 100% stents. Assures the perfect surface finishing. Accurate dimensional analysis of the stent struts. 3D control, struts 100% checked.

Peripheral

iVolution pro

Post author By abhishek
Post date August 13, 2022

iVolution pro

Self-expanding peripheral stent system
Bring precision to treat your patients

PRODUCT FEATURES

Optimum visibility

iVolution pro has 2 markers delimiting the stent and 1 tungsten marker in the retractable sheath, indicating the implantation level.

Controlled and easy deployment

User-friendly stent thanks to its triple sheath design and ergonomic small handle. The deployment speed is modulated through the handle’s wheel.

Flexible and resistant stent design

The stress is homogeneously distributed to avoid stent fracture. iVolution pro open cell design offers the highest flexibility.

CLINICAL SUPPORT

iVolution pro has demonstrated its safety and efficacy in the following clinical trials

EVOLUTION Trial

Prospective, multicenter trial in femoropopliteal TASC A&B lesions. 88.0% fTLR at 1 year

TINTIN Trial

Prospective, multicenter trial, with Luminor and iVolution combined therapy in TASC C&D lesions. 89.4% fTLR at 2 years

Yukon Choice PC

TECHNICAL DATA

PRODUCT MATRIX / ORDERING INFORMATION*

COMPLIANCE CHART

Yukon Choice PC Elite

VIVO ISAR

ISAR SUMMIT

TECHNOLOGY THAT SHALL REDEFINE THE PERFORMANCE OF DRUG ELUTING STENTS

TECHNOLOGY THAT SHALL REDEFINE THE PERFORMANCE OF DRUG ELUTING STENTS

ORDERING INFORMATION

COMPLIANCE CHART

Oceanus

Oceanus

Angiolite BTK

ANGIOLITE BTK Trial

Sergeant

Restorer

Low restenosis

Q six, the certified quality of all iVascular stents

iVolution pro

EVOLUTION Trial

TINTIN Trial

Recent Posts

Recent Comments

Archives

Categories

Our Marketing

Company

Newsletter